References

  1. 1. YUPELRI [package insert]. Morgantown, WV: Mylan Specialty LP.
  2. 2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD: 2024 report. Global Initiative for Chronic Obstructive Lung Disease, Inc. Accessed October 21, 2024. https://goldcopd.org/2024-gold-report/
  3. 3. Gardenhire DS, Burnett D, Strickland S, Myers TR. A guide to aerosol delivery devices for respiratory therapists. 4th ed. Irving, TX: American Association for Respiratory Care; 2017.
  4. 4. Nebulizers—Policy Article. Centers for Medicare & Medicaid Services website. Published October 1, 2015. Updated January 1, 2024. Accessed October 21, 2024. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52466
  5. 5. Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(10):1333-1343.
  6. 6. Schure MB, Borson S, Nguyen HQ, et al. Associations of cognition with physical functioning and health-related quality of life among COPD patients. Respir Med. 2016;114:46-52.
  7. 7. Baird C, Lovell J, Johnson M, Shiell K, Ibrahim JE. The impact of cognitive impairment on self-management in chronic obstructive pulmonary disease: a systematic review. Respir Med. 2017;129:130-139.
  8. 8. Hanania NA, Braman S, Adams SG, et al. The role of inhalation delivery devices in COPD: perspectives of patients and health care providers. Chronic Obstr Pulm Dis. 2018;5(2):111-123.
  9. 9. Wise RA, Acevedo RA, Anzueto AR, et al. Guiding principles for the use of nebulized long-acting beta2-agonists in patients with COPD: an expert panel consensus. Chronic Obstr Pulm Dis. 2016;4(1):7-20.
  10. 10. Celli BR, Navaie M, Xu Z, Cho-Reyes S, Dembek C, Gilmer TP. Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment. Int J Chron Obstruct Pulmon Dis. 2019;14:1019-1031.
  11. 11. Diette GB, Dalal AA, D Souza AO, Lunacsek OE, Nagar SP. Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States. Int J Chron Obstruct Pulmon Dis. 2015;10:415-422.
  12. 12. Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26(3):174-179.
  13. 13. Sharma G, Mahler DA, Mayorga VM, Deering KL, Harshaw O, Ganapathy V. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chronic Obstr Pulm Dis. 2017;4(3):217-224.
  14. 14. Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis. 2016;12:59-71.
  15. 15. Dhand R, Dolovich M, Chipps B, Myers TR, Restrepo R, Farrar JR. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD. 2012;9(1):58-72.
  16. 16. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011;377(9770):1032-1045.
  17. 17. Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Devices (Auckl). 2015;8:131-139.
  18. 18. Martin AR, Finlay WH. Nebulizers for drug delivery to the lungs. Expert Opin Drug Deliv. 2015;12(6):889-900.
  19. 19. De Vries M, Garner S, Hartley C, Stocking J. Pulmonary disease aerosol delivery devices: a guide for physicians, nurses, pharmacists, and other health care professionals, 4th ed. American Association for Respiratory Care. Accessed December 4, 2024. https://www.aarc.org/wp-content/uploads/2023/06/aerosol_guide_for_HCPs_4th_ed.pdf
  20. 20. Goldman RE, Mennillo L, Stebbins P, Parker DR. How do patients conceptualize chronic obstructive pulmonary disease? Chron Respir Dis. 2017:14(3);245-255.
  21. 21. Sigurgeirsdottir J, Halldorsdottir S, Arnardottir RH, Gudmundsson G, Bjornsson EH. Frustrated caring: Family members' experience of motivating COPD patients towards self-management. Int J Chron Obstruct Pulmon Dis. 2020;15:2953-2965.
  22. 22. Berger BE, Kapella MC, Larson JL. The experience of stigma in chronic obstructive pulmonary disease. West J Nurs Res. 2011;33(7):916-932.
  23. 23. Johnson JL, Campbell AC, Bowers M, Nichol AM. Understanding the social consequences of chronic obstructive pulmonary disease: the effects of stigma and gender. Proc Am Thorac Soc. 2007;4(8):680-682.
  24. 24. Taber JM, Leyva B, Persoskie A. Why do people avoid medical care? A qualitative study using national data. J Gen Intern Med. 2015;30(3):290-297.
  25. 25. Data on file. Mylan Specialty LP, a Viatris Company.
  26. 26. Pudi KK, Barnes CN, Moran EJ, Haumann B, Kerwin E. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017;18(1):182.
  27. 27. St. George's Respiratory Questionnaire. American Thoracic Society website. Accessed October 21, 2024. https://www.thoracic.org/members/assemblies/assemblies/srn/questionaires/sgrq.php
  28. 28. Long-acting medication use in COPD: opportunities for minimizing medication waste in the hospital setting. Pharm Times. November 2017. Accessed October 21, 2024. https://pharmacytimes.s3.amazonaws.com/v1_media/RESP242-17-%20Pharmacy%20Times%20Unused%20Canister%20White%20Paper_FINAL.pdf
  29. 29. Costs. Medicare.gov. Accessed October 21, 2024. https://www.medicare.gov/basics/costs/medicare-costs
  30. 30. Centers for Medicare & Medicaid Services. MLN Matters. Number MM8304. Accessed October 21, 2024. https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2013-Transmittals-Items/R468PI
  31. 31. Centers for Medicare & Medicaid Services. Medicare claims processing manual. Chapter 17—drugs and biologicals (rev. 12511; issued 2-15-24). Accessed October 21, 2024. https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c17.pdf